Animal models of Alzheimer disease.
暂无分享,去创建一个
[1] M. Staufenbiel,et al. Extracellular amyloid formation and associated pathology in neural grafts , 2003, Nature Neuroscience.
[2] D. Price,et al. Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice , 2008, Proceedings of the National Academy of Sciences.
[3] J. Hardy,et al. Aβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice , 2005, Neuron.
[4] I. Kola,et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. , 2001, Human molecular genetics.
[5] David G. Tew,et al. Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase , 1999, Molecular and Cellular Neuroscience.
[6] Kim N. Green,et al. Intracellular amyloid-β in Alzheimer's disease , 2007, Nature Reviews Neuroscience.
[7] K. Davis,et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. , 2000, JAMA.
[8] D. Price,et al. Reduced BACE1 Activity Enhances Clearance of Myelin Debris and Regeneration of Axons in the Injured Peripheral Nervous System , 2011, The Journal of Neuroscience.
[9] D. Wilcock,et al. Intrahippocampal LPS injections reduce Aβ load in APP+PS1 transgenic mice , 2001, Neurobiology of Aging.
[10] S. Oddo,et al. The ubiquitin-proteasome system in Alzheimer's disease , 2008, Journal of cellular and molecular medicine.
[11] F. LaFerla,et al. Intracellular amyloid-beta in Alzheimer's disease. , 2007, Nature reviews. Neuroscience.
[12] C. Holmes,et al. Neuropathology after active Aβ42 immunotherapy: implications for Alzheimer’s disease pathogenesis , 2010, Acta Neuropathologica.
[13] A. Palmeri,et al. Phosphodiesterase 5 Inhibition Improves Synaptic Function, Memory, and Amyloid-β Load in an Alzheimer's Disease Mouse Model , 2009, The Journal of Neuroscience.
[14] T. Iwatsubo,et al. A Noncompetitive BACE1 Inhibitor TAK-070 Ameliorates Aβ Pathology and Behavioral Deficits in a Mouse Model of Alzheimer's Disease , 2010, The Journal of Neuroscience.
[15] J. Treanor,et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.
[16] D. Sirinathsinghji,et al. Mice Deficient for the Amyloid Precursor Protein Gene , 1996, Annals of the New York Academy of Sciences.
[17] D. Selkoe,et al. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.
[18] D. Westaway,et al. Lysosomal Proteolysis and Autophagy Require Presenilin 1 and Are Disrupted by Alzheimer-Related PS1 Mutations , 2010, Cell.
[19] G. Münch,et al. The molecular basis of the prevention of Alzheimer’s disease through healthy nutrition , 2007, Experimental Gerontology.
[20] L. Mucke,et al. Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.
[21] David C. Lee,et al. TACE/ADAM17 Processing of EGFR Ligands Indicates a Role as a Physiological Convertase , 2003, Annals of the New York Academy of Sciences.
[22] A. Marighetto,et al. Comparative effects of the α7 nicotinic partial agonist, S 24795, and the cholinesterase inhibitor, donepezil, against aging-related deficits in declarative and working memory in mice , 2008, Psychopharmacology.
[23] F. LaFerla,et al. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease , 2003, Neurobiology of Aging.
[24] Tony Wyss-Coray,et al. Inflammation in Neurodegenerative Disease—A Double-Edged Sword , 2002, Neuron.
[25] F. LaFerla,et al. Pathways by which Abeta facilitates tau pathology. , 2006, Current Alzheimer research.
[26] C. Sanders,et al. Substrate specificity of γ-secretase and other intramembrane proteases , 2008, Cellular and Molecular Life Sciences.
[27] M. Mattson,et al. Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.
[28] H. Cai,et al. BACE1, a Major Determinant of Selective Vulnerability of the Brain to Amyloid-β Amyloidogenesis, is Essential for Cognitive, Emotional, and Synaptic Functions , 2005, The Journal of Neuroscience.
[29] W. Markesbery,et al. Impaired Proteasome Function in Alzheimer's Disease , 2000, Journal of neurochemistry.
[30] Anatol C. Kreitzer,et al. Aberrant Excitatory Neuronal Activity and Compensatory Remodeling of Inhibitory Hippocampal Circuits in Mouse Models of Alzheimer's Disease , 2007, Neuron.
[31] D. Salmon,et al. Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.
[32] T. Montine,et al. Quantitation and Mapping of Cerebral Detergent‐Insoluble Proteins in the Elderly , 2009, Brain pathology.
[33] J. Trojanowski,et al. The Levels of Soluble versus Insoluble Brain Aβ Distinguish Alzheimer's Disease from Normal and Pathologic Aging , 1999, Experimental Neurology.
[34] D. Westaway,et al. Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model , 2006, Nature Medicine.
[35] Julie R. Leitz,et al. Tau Protein Is Required for Amyloid β-Induced Impairment of Hippocampal Long-Term Potentiation , 2011, The Journal of Neuroscience.
[36] F. LaFerla,et al. Lipopolysaccharide-Induced Inflammation Exacerbates Tau Pathology by a Cyclin-Dependent Kinase 5-Mediated Pathway in a Transgenic Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.
[37] R. Kayed,et al. Soluble Aβ oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain , 2005, Brain Research.
[38] S. Tonegawa,et al. Skeletal and CNS Defects in Presenilin-1-Deficient Mice , 1997, Cell.
[39] K. Blennow,et al. PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. , 2010, Journal of Alzheimer's disease : JAD.
[40] R. Schliebs,et al. Induction of cytokines in glial cells surrounding cortical β-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology , 2000, International Journal of Developmental Neuroscience.
[41] A. Smith,et al. Relative roles of plaques and tangles in the dementia of Alzheimer's disease: correlations using three sets of neuropathological criteria. , 1995, Dementia.
[42] T. Bayer,et al. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. , 2004, The American journal of pathology.
[43] R. Barbour,et al. Purification and cloning of amyloid precursor protein β-secretase from human brain , 1999, Nature.
[44] C. Glabe,et al. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction , 2009, Neurobiology of Disease.
[45] B. Trapp,et al. Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[46] W. Richards,et al. Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation , 2001, Nature Neuroscience.
[47] D. Holtzman,et al. Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s disease , 2008, Nature.
[48] P. Jeffrey,et al. Oral administration of a potent and selective non‐peptidic BACE‐1 inhibitor decreases β‐cleavage of amyloid precursor protein and amyloid‐β production in vivo , 2007 .
[49] D. Selkoe,et al. Aβ Oligomers – a decade of discovery , 2007, Journal of neurochemistry.
[50] T. Poulos,et al. The mouse C1q A-chain sequence alters beta-amyloid-induced complement activation☆ , 1999, Neurobiology of Aging.
[51] Alison R. Gregro,et al. First Demonstration of Cerebrospinal Fluid and Plasma Aβ Lowering with Oral Administration of a β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor in Nonhuman Primates , 2009, Journal of Pharmacology and Experimental Therapeutics.
[52] M. Ball,et al. Water-soluble A(N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains (*) , 1996, The Journal of Biological Chemistry.
[53] P. Saftig,et al. Klotho is a substrate for α‐, β‐ and γ‐secretase , 2009 .
[54] P. Wong,et al. Bace1 modulates myelination in the central and peripheral nervous system , 2006, Nature Neuroscience.
[55] Rudi D'Hooge,et al. Phenotypic and Biochemical Analyses of BACE1- and BACE2-deficient Mice* , 2005, Journal of Biological Chemistry.
[56] Jürgen Götz,et al. A Decade of Tau Transgenic Animal Models and Beyond , 2007, Brain pathology.
[57] M. Ohno,et al. BACE1 Deficiency Rescues Memory Deficits and Cholinergic Dysfunction in a Mouse Model of Alzheimer's Disease , 2004, Neuron.
[58] Nastaran Gharkholonarehe,et al. Progression of Amyloid Pathology to Alzheimer's Disease Pathology in an Amyloid Precursor Protein Transgenic Mouse Model by Removal of Nitric Oxide Synthase 2 , 2008, The Journal of Neuroscience.
[59] J. Troncoso,et al. Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome. , 2001, Archives of pathology & laboratory medicine.
[60] N. Schor. What the halted phase III γ‐secretase inhibitor trial may (or may not) be telling us , 2011, Annals of neurology.
[61] J. D. McGaugh,et al. Intraneuronal Aβ Causes the Onset of Early Alzheimer’s Disease-Related Cognitive Deficits in Transgenic Mice , 2005, Neuron.
[62] P. Saftig,et al. Control of Peripheral Nerve Myelination by the ß-Secretase BACE1 , 2006, Science.
[63] B. de Strooper,et al. β Subunits of Voltage-gated Sodium Channels Are Novel Substrates of β-Site Amyloid Precursor Protein-cleaving Enzyme (BACE1) and γ-Secretase* , 2005, Journal of Biological Chemistry.
[64] Kim N. Green,et al. Linking Calcium to Aβ and Alzheimer's Disease , 2008, Neuron.
[65] D. Walsh,et al. Exogenous Induction of Cerebral ß-Amyloidogenesis Is Governed by Agent and Host , 2006, Science.
[66] R. Motter,et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.
[67] Anne W. Schmidt,et al. Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy. , 2009, Journal of medicinal chemistry.
[68] Michael A. Briggs,et al. GSK189254, a Novel H3 Receptor Antagonist That Binds to Histamine H3 Receptors in Alzheimer's Disease Brain and Improves Cognitive Performance in Preclinical Models , 2007, Journal of Pharmacology and Experimental Therapeutics.
[69] H. Vanderstichele,et al. Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[70] J. Hardy,et al. Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.
[71] N. Hirokawa,et al. Defects in Axonal Elongation and Neuronal Migration in Mice with Disrupted tau and map1b Genes , 2000, The Journal of cell biology.
[72] Huaxi Xu,et al. Presenilin/γ-secretase-dependent processing of β-amyloid precursor protein regulates EGF receptor expression , 2007, Proceedings of the National Academy of Sciences.
[73] Yongzhou Hu,et al. Progress in the development of nonpeptidomimetic BACE 1 inhibitors for Alzheimer's disease. , 2009, Current medicinal chemistry.
[74] F. LaFerla,et al. Neural Stem Cells Improve Memory in an Inducible Mouse Model of Neuronal Loss , 2007, The Journal of Neuroscience.
[75] David H. Cribbs,et al. Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome , 2004, Neuron.
[76] D. Morgan. Immunotherapy for Alzheimer’s disease , 2011, Journal of internal medicine.
[77] F. LaFerla,et al. Presenilin Is Necessary for Efficient Proteolysis through the Autophagy–Lysosome System in a γ-Secretase-Independent Manner , 2011, The Journal of Neuroscience.
[78] Arun K. Ghosh,et al. In vivo inhibition of Aβ production by memapsin 2 (β‐secretase) inhibitors , 2004, Journal of neurochemistry.
[79] Doo Yeon Kim,et al. Reduced Sodium Channel Nav1.1 Levels in BACE1-null Mice* , 2010, The Journal of Biological Chemistry.
[80] M. Staufenbiel,et al. Macrocyclic BACE-1 inhibitors acutely reduce Abeta in brain after po application. , 2010, Bioorganic & medicinal chemistry letters.
[81] K. Ashe,et al. Plaque-associated alpha-synuclein (NACP) pathology in aged transgenic mice expressing amyloid precursor protein. , 2000, Brain research.
[82] B. de Strooper,et al. The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. , 2002, Human molecular genetics.
[83] M. Findeis. The role of amyloid β peptide 42 in Alzheimer's disease , 2007 .
[84] C. Masters,et al. Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs Is Associated with Decreased Interstitial Aβ , 2008, Neuron.
[85] D. Selkoe,et al. Intraneuronal Abeta42 accumulation in Down syndrome brain. , 2002, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[86] Jürgen Götz,et al. Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models , 2010, Cell.
[87] K. Ashe,et al. Tau Mislocalization to Dendritic Spines Mediates Synaptic Dysfunction Independently of Neurodegeneration , 2010, Neuron.